Study of Surgery Plus Drug Treatment Versus Drug Treatment Alone for Breast Cancer That Has Spread to the Liver

What this Trial Is About

Breast cancer is a common cancer with a significant number of cases involving liver metastases, which are cancer spread to the liver. This trial is designed to compare the effects of adding local surgical treatment for liver metastases to standard systemic cancer treatment for patients with advanced breast cancer, aiming to improve survival and quality of life. Researchers will also study the safety of these treatments and factors that might predict patient outcomes during both surgical and oncological care. The trial includes two groups one receiving surgery to remove or treat liver metastases through methods like liver resection, ablation, or stereotactic body radiotherapy alongside standard cancer treatment, and a control group receiving only systemic oncological treatment. Surgery candidates must have 1 to 4 liver metastases suitable for removal and stable or improving disease after initial cancer therapy. Treatment and follow-up are planned across multiple centers. Participants will be monitored for survival over three years after randomization, with evaluations of overall survival, progression-free survival, and quality of life. The study will track safety throughout treatment and collect information on how well patients respond to therapies. Total participation time covers years following the initial treatment to assess long-term outcomes.

BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases